Tirzepatide
Dual GIP/GLP-1 agonist approved in several regions for T2D and obesity (brand-dependent).
Overview
Often compared head-to-head with GLP-1 mono-agonists in clinical discourse.
What it is
Synthetic dual GIP and GLP-1 receptor agonist peptide.
Mechanism (high level)
Co-activation of GIPR and GLP-1R improves glycemic control and supports weight loss in trials.
Quick facts
- Dosage
- Per label — weekly titration schedules
- Route
- Subcutaneous
- Cycle
- Long-term maintenance when prescribed
- Storage
- Refrigerate pens per label until use
Research indications
- T2D
- Obesity where indicated
Research protocols (education)
Education-first logging template
Use PepTok to track adherence and notes; any protocol must be directed by a qualified clinician.
Interactions
Often avoided with
- Concurrent GLP-1 without medical reconciliation
Often combined with
- Nutrition support
- retinopathy surveillance when indicated
Peptides discussed online are not substitutes for diagnosis or prescriptions.
Side effects & safety
- GI effects; rare gallbladder disease — seek care for severe pain.
Regulatory notes
- Rx-only; approved indications vary by brand/region.
FAQ
Is this a prescription?
PepTok does not provide prescriptions; it is for logging and education.
Related in catalog
Track in app
Save favorites, compare protocols, and track over time
PepTok gives you structure: stacks, reminders, notes, and progress snapshots in one place.
Educational content only. This material is not medical advice. Verify legality, sourcing, and dosing with a qualified professional.